Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

DAILY VOLUME INDEX


Last Signal:

BEARISH


Trading: SELL @ $16.3
Signal Strength: MEDIUM
Recommendation:

Clinuvel Pharmaceuticals (ASX:CUV) current distribution has given weakness to the share price and the continuation of bearish trading conditions. Currently, the DVI is -226.


Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading exit. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.


The daily volume index (DVI) is the amount of individual securities traded in a day on average over a specified period of time. Trading activity relates to the liquidity of a security. When average daily trading volume is high the stock can be easily traded and has high liquidity if trading volume is not very high and the security will tend to be less expensive because people are not as willing to buy it. As a result average daily trading volume can have an effect on the price of the security.

Calculation: Daily Volume Index (DVI):
1) [Close]-[Average price] / [Average price] x [Volume];


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Daily Volume Index

Download button icon Download
Company Close Change (%) Volume Value Signal
TRS Reject Shop 2.77 14 1,255,477 -906 BEARISH
MNF My Net Fone 3.83 4.4 45,912 -494 BEARISH
SHM Shriro 0.69 3.8 27,413 -6,790 BEARISH
CLH Collection House 1.27 3.7 306,389 -820 BEARISH
REA REA Group 74.75 3.5 228,972 -699 BEARISH
FDV Frontier Digital Ventures 0.5 3.1 136,108 -836 BEARISH
CAR Carsales 11.58 3.1 1,731,560 -2,347 BEARISH
AGI Ainsworth Game Technology 0.94 2.7 398,314 -1,706 BEARISH
COH Cochlear 162.66 2.5 312,905 -106 BEARISH
SGP Stockland 3.65 2.5 9,004,378 -11,290 BEARISH
back to top